Asia-Pacific Next Generation Sequencing (NGS) Market by Offering (Kits [Library Prep, QC, DNA Extraction], System), Type (Genome, Exome, Targeted), Application (Reproductive, Oncology), Technology (SBS, Nanopore, Nanoball, SMRT Seq) – Forecast to 2030

The Asia-Pacific Next Generation Sequencing (NGS) Market is expected to grow at a CAGR of 16.9% from 2024 to 2030 to reach $6.38 billion by 2030. Next Generation Sequencing (NGS) is a technology used to sequence the orientation of nucleotides in genetic material. This technology enables the sequencing of DNA or RNA more quickly and at a lower cost compared to Sanger sequencing. Continuous developments in NGS technology are revolutionizing the field of personalized medicine, genetic diseases, and clinical diagnostics by providing the capability to sequence multiple individuals with a variable genetic orientation simultaneously.

The growth of this market is driven by factors such as the rising cancer prevalence and increasing application of NGS in cancer treatment and research, the declining costs of genome sequencing, technological advancements in sequencing procedures, and increasing pharmaceutical R&D expenditures. However, the high costs of NGS systems and consumables and the availability of alternative technologies restrain the market's growth.

Additionally, the increasing applications of NGS, the rising adoption of bioinformatics and genomic data management solutions, and government initiatives supporting large-scale genomic sequencing projects are expected to offer significant market growth opportunities. However, the lack of skilled professionals and regulatory and standardization concerns in diagnostic testing pose a significant challenge to the market's growth.

Click here to: Get Free Sample Pages of this Report

Rising Cancer Prevalence and Increasing Application of NGS in Cancer Treatment and Research Driving the Market's Growth

The prevalence of cancer is rising across the world. According to GLOBOCAN, in 2020, 9.5 million people were diagnosed with cancer in Asia–Pacific. This number is expected to rise to 12.3 million by 2030. The most common types of cancer are lung cancer, breast cancer, colon cancer, prostate cancer, and rectum cancer. According to the data published by the World Health Organization (WHO) in February 2022, cancer was among the most common cause of mortality all over the world. In 2020, it accounted for approximately 10 million deaths. Further, according to India Against Cancer, 2.7 million people were diagnosed with cancer in 2020.

The utilization of NGS is also growing in cancer treatment and research. NGS has been proven as an effective method for gaining a more precise and comprehensive understanding of the molecular foundations of individual cancers. Targeted medicines are quickly becoming the new standard of care for cancer. Also, NGS is currently starting to be used in clinical oncology to improve cancer therapy through a variety of techniques, including the discovery of novel and rare cancer mutations, the identification of cancer mutation carriers, and the development of specialized therapeutic approaches known as personalized medicine (PM). Further, NGS has the additional advantage of offering an expanded view of the disease landscape and revealing cancer development pathways. Thus, the rising cancer prevalence and increasing application of NGS in cancer treatment and research drive the demand for NGS in Asia–Pacific.

The Increasing Applications of NGS Create an Opportunity for the Market

NGS has gained much significance in clinical practices for oncology, reproductive health, Mendelian disorders, complex diseases, and infectious diseases. In the coming years, NGS is expected to diversify in other clinical areas, with a considerable reduction in sequencing costs. The technology is expected to show substantial penetration in applications such as liquid biopsies for the early detection and monitoring of cancer and reproductive health applications. New biomarkers and actionable mutations are being identified by researchers, which are consequently expected to increase the applications and usage of NGS technology, creating growth opportunities for the players operating in the NGS market.

Key Findings in the Asia–Pacific NGS Market Study:

The Consumables Segment is Expected to Account for the Largest Share of the Market in 2024

Among the offerings, in 2024, the consumables segment is expected to account for the largest share of the Asia–Pacific NGS market by offering. The recurring use of consumables, rising demand for NGS-based diagnostic tests, and increasing applications of NGS in oncology, reproductive health diagnosis, and drug discovery are increasing the demand for consumables.

The Targeted Genome Sequencing Segment is Expected to Account for the Largest Share of the Market in 2024

Among sequencing types, the targeted genome sequencing segment is expected to account for the largest share of the NGS market in 2024. The large share of this segment is attributed to rapid and cost-effective methods, applications in discovering somatic mutations in complex samples such as cancerous tumors mixed with germline DNA, and a high cult of researchers for targeted genome sequencing to study gene-drug associations is expected to drive the targeted genome sequencing segment.

The Sequencing by Synthesis Segment is Expected to Account for the Largest Share of the Market in 2024

Among the technologies, the sequencing by synthesis segment is expected to account for the largest share of the Asia–Pacific NGS market. The key factors supporting the large market share of this segment are highly accurate output with base-by-base sequencing using sequencing by synthesis, reducing sequence-specific errors, and enabling robust base calling across the entire genome, including repetitive sequences and homopolymers.

The Research and Other Applications is Expected to Account for the Largest Share of the Market in 2024

Among the applications, in 2024, the research and other applications segment is expected to account for the largest share of the Asia–Pacific NGS market. The growing prevalence of genetic disorders, the increasing adoption of sequencing-based tests in laboratories, the growing demand for personalized medicines, and the increasing NGS-based research are factors contributing to the significant market share of this segment.

The Pharmaceutical & Biotechnology Companies Segment is Expected to Account for the Largest Share of the Asia–Pacific NGS Market in 2024

Among the end users, in 2024, the pharmaceutical & biotechnology segment is expected to account for the largest share of the Asia–Pacific NGS market. The large market share of this segment is attributed to factors such as the increasing R&D spending by pharmaceutical & biotechnology companies and the rising incidence of chronic diseases, which drive the adoption of NGS among pharmaceutical & biotechnology companies.

China to Account for the Largest Market Share in 2024

In 2024, China is expected to account for the largest share of the Asia–Pacific NGS market. The large share is primarily attributed to the increasing government focus on sequencing projects, the establishment of new healthcare facilities and modernizing existing ones, the large pool of patients with gene-associated disorders, and growing research activities for developing personalized medicines.

Key Players

The report includes a competitive landscape based on an extensive assessment of the key strategic developments that led market participants to adopt over the past three years 2020–2024. The key players profiled in the Asia–Pacific NGS market report are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and 10X Genomics, Inc. (U.S.).

Scope of the Report:

Asia–Pacific NGS Market Assessment, by Offering

• Consumables
  • Sample Preparation Consumables
    • DNA Extraction and Amplification
    • Library Preparation & Target Enrichment
    • Quality Control
  • Other Consumables
• NGS Platforms/Instruments
• Software
• Services
  (Note: Other consumables include vials, pipettes, containers, trays, sequencing reagents, flow cells, and tubes.)

Asia–Pacific NGS Market Assessment, by Sequencing Type

• Targeted Genome Sequencing
• Whole Genome Sequencing
• Whole Exome Sequencing
• Other Sequencing Types
  (Note: Other sequencing types include degradome sequencing, chromatin immunoprecipitation (ChIP) sequencing, and methylation sequencing.)

Asia–Pacific NGS Market Assessment, by Technology

• Sequencing by Synthesis
• Ion Semiconductor Sequencing
• Single-molecule Real-time Sequencing (SMRT)
• Nanopore Sequencing
• DNA nanoball sequencing
  (Note: Other sequencing technologies include polony sequencing, sequencing by ligation, pyrosequencing, and true single molecule sequencing (tSMS).)

Asia–Pacific NGS Market Assessment, by Application

• Research Applications
  • Drug Discovery
  • Agriculture & Animal Research
  • Other Research Applications
• Clinical Applications
  • Reproductive Health Diagnosis
  • Oncology
  • Infectious Diseases
  • Other Clinical Applications
    (Note: Other research applications include food microbiology, microbiota analysis in the beverage industry, and environmental studies, and other clinical applications include the detection of genetic aberrations in neurological disorders, rare diseases, metabolic and immune disorders, and food-borne illnesses.)

Asia–Pacific NGS Market Assessment, by End User

• Hospitals and Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Academic Institutes & Research Centers
• Other End Users
  (Note: Other end users include forensic laboratories & security agencies, food & beverage companies, and agriculture companies.)

Asia–Pacific NGS Market Assessment, by Geography

• China
• Japan
• India
• Singapore
• Australia
• Malaysia
• New Zealand
• Rest of Asia-Pacific (RoAPAC)

Key questions answered in the report: